Bangladesh indicators MoU with India for 30 million doses of Oxford’s coronavirus vaccine

As per the MoU, Pune-based SII will present Bangladesh with 30 million doses of University of Oxford’s Covid-19 vaccine candidate ‘Covishield’ by means of Bexmico Pharmaceuticals.

SII, Bangladesh govt and Beximco Pharmaceuticals officers signing the MoU in Dhaka on Thursday (Photo Credits: Sahidul Hasan Khokon/India Today)

Bangladesh authorities on Thursday signed an MoU with Pune-based SII and Bexmico Pharmaceuticals to obtain 30 million doses of ‘Covishield’. The Covid-19 vaccine candidate is being developed by the University of Oxford in collaboration with AstraZeneca and the Serum Institute of India (SII).

A Memorandum of Understanding (MoU) to that impact was signed by officers from Bangladesh’s Ministry of Health and Family Welfare, SII and Bexmico Pharmaceuticals in Dhaka on Thursday. The MoU talks about 30 million doses of the University of Oxford’s coronavirus vaccine candidate ‘Covishield’ for Bangladesh.

Bangladesh Health Minister Zahed Maleque, Indian High Commissioner in Dhaka Vikram Doraiswami and Managing Director (MD) of Beximco Pharmaceuticals Nazmul Hassan Papon have been current through the occasion in Dhaka.

As per the MoU, Serum Institute of India will present the Covid-19 vaccine to Beximco Pharmaceuticals Ltd.

“Once the vaccine is developed, the Serum Institute will provide 30 million doses of vaccine in the first phase, and BPL will bring it to Bangladesh. Including the cost of delivery will cost 5 US dollars per dose 425 in Bangladeshi currency,” Bangladesh Health Minister Zahed Maleque mentioned.

Minister Maleque added, “We would be able to provide the vaccine to 1.5 crore people once it’s available in Bangladesh as two shots of vaccine are needed for one person.”

Developed by the University of Oxford, Covishield is present process Phase-2 of scientific trials. The CEO of SII, Adar Poonawalla mentioned earlier this week that likelihood is that the trials will full by December 2020.

However, Poonawalla mentioned it’s too early to touch upon the vaccine’s availability.

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *